Patent SG-11201806342S-A (SG)
Title: Glucagon and glp-1 co-agonists for the treatment of obesity
Inventor: BEDNAREK MARIA
IPC: A61P9/12
Filed: 2017-03-10
Abstract: aVehicle (buffer) * Liraglfffide .6 nmoIrkg • inuArkg 4 GAO 20 nmobkg G730 50 nmol.fkg Bo dy we ig ht ( % c hang e o f day 0) -12 -14 -16 -18 -20 -22 -24 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/153575 Al 14 September 2017 (14.09.2017) WIPO I PCT (51) International Patent Classification: A61K 38/26 (2006.01) A61P 3/10 (2006.01) A61P 3/04 (2006.01) A61P 9/12 (2006.01) A61P 3/06 (2006.01) (21) International Application Number: PCT/EP2017/055679 (22) International Filing Date: 10 March 2017 (10.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/306,121 10 March 2016 (10.03.2016) US (71) Applicant: MEDIMMUNE LIMITED [GB/GB]; Mil- stein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). (72) Inventors: BEDNAREK, Maria, Aleksandra; MedIm- mune Limited Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). JERMUTUS, Lutz, Ul- rich; Milstein Building Granta Park, Cambridge Cam- bridgeshire CB21 6GH (GB). AMBERY, Philip; Milstein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). PETRONE, Marcella; Milstein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). (74) Agent: TTOFI, Evangelia; Milstein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) = (54) Title: GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY 111111111111110111011111111111010111110 III 011110110111100111111111111111111110111111 W O 20 17 / 15 3575 Al 0 1 2 3 4 5 6 7 0 11 12 13 14 Dosing day FIG. 1 (57) : Provided herein are methods of preventing and treating obesity and diabetes in patients comprising administering GLP-1/glucagon agonist peptides.